Back

Safety and efficacy of mavacamten compared to alcohol septal ablation in hypertrophic obstructive cardiomyopathy in a retrospective real-world cohort

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (3) Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Viktoria Santner

Medical University of Graz, Graz (Austria)

8 More presentations in this session

Presentation thumbnail
Comparisons in clinical outcomes for pediatric patients diagnosed with hypertrophic cardiomyopathy
Professor J. Conway (Edmonton, CA)
Abstract
Presentation thumbnail
Real-world predictors of adverse outcomes in hcm: who is really at risk?
Doctor D. Ferreira (Lisbon, PT)
Abstract
Presentation thumbnail
Outcomes of patients with hypertrophic cardiomyopathy after evaluation at a comprehensive hypertrophic cardiomyopathy center
Doctor N. Reza (Philadelphia, US)
Abstract
Presentation thumbnail
The burden of hypertrophic cardiomyopathy-related major adverse cardiovascular events prior to comprehensive HCM care
Doctor N. Reza (Philadelphia, US)
Abstract
Presentation thumbnail
Clinical course and outcomes of patients with hypertrophic cardiomyopathy prior to evaluation at a comprehensive hypertrophic cardiomyopathy center
Doctor N. Reza (Philadelphia, US)
Abstract

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (3)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources